Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ARNOTT

Showing results (1091-1100 of 1,193) with videos related to

Pageof 120
Sort By:
Schizophrenia (Heidelberg, Germany)|January 9, 2023
Gray matter volume drives the brain age gap in schizophrenia: a SHAP studyPedro L Ballester, Jee Su Suh, Natalie C W Ho, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 26, 2025
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l'étude CAN-BIND-1Chloé Stengel, Benjamin Schwartzmann, Raaj Chatterjee, et al.
Geroscience|June 7, 2025
Subcortical white matter hyperintensities and motor function in parkinson's disease: findings from the ONDRI studyDaniela Cristina Carvalho de Abreu, Frederico Pieruccini-Faria, Anthony E Lang, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Translational Psychiatry|October 11, 2024
Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volumeRaegan Mazurka, Kate L Harkness, Stefanie Hassel, et al.
Emerging Infectious Diseases|October 24, 2024
Vibrio parahaemolyticus Foodborne Illness Associated with Oysters, Australia, 2021-2022Emily Fearnley, Lex E X Leong, Alessia Centofanti, et al.
Pharmacy (Basel, Switzerland)|December 22, 2019
A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of TherapeuticsBrian J Piper, Alexandria A Alinea, John R Wroblewski, et al.
Neuroimage. Clinical|June 24, 2023
The development of the pediatric stroke neuroimaging platform (PEDSNIP)Trish Domi, Amanda Robertson, Wayne Lee, et al.
Pageof 120

Showing results (1091-1100 of 1,193) with videos related to

Sort By:
Pageof 120
Schizophrenia (Heidelberg, Germany)|January 9, 2023
Gray matter volume drives the brain age gap in schizophrenia: a SHAP studyPedro L Ballester, Jee Su Suh, Natalie C W Ho, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 26, 2025
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l'étude CAN-BIND-1Chloé Stengel, Benjamin Schwartzmann, Raaj Chatterjee, et al.
Geroscience|June 7, 2025
Subcortical white matter hyperintensities and motor function in parkinson's disease: findings from the ONDRI studyDaniela Cristina Carvalho de Abreu, Frederico Pieruccini-Faria, Anthony E Lang, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Translational Psychiatry|October 11, 2024
Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volumeRaegan Mazurka, Kate L Harkness, Stefanie Hassel, et al.
Emerging Infectious Diseases|October 24, 2024
Vibrio parahaemolyticus Foodborne Illness Associated with Oysters, Australia, 2021-2022Emily Fearnley, Lex E X Leong, Alessia Centofanti, et al.
Pharmacy (Basel, Switzerland)|December 22, 2019
A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of TherapeuticsBrian J Piper, Alexandria A Alinea, John R Wroblewski, et al.
Neuroimage. Clinical|June 24, 2023
The development of the pediatric stroke neuroimaging platform (PEDSNIP)Trish Domi, Amanda Robertson, Wayne Lee, et al.
Pageof 120